Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

Keep reading to learn about the link between obesity and MASH and how to reduce your risk of this disease. “MASH is a dysfunction of the liver caused by excess fat cells,” says Mir Ali ...

MASH, which was previously known as non–alcohol related steatohepatitis (NASH), is often asymptomatic or leads to nonspecific symptoms, making progression to more severe stages of liver disease ...

Two teens are on the way to a Halloween party dressed as Romeo and Juliet when their car breaks down in front of a sinister mansion. Seeking help, they fall into a party of monsters led by Dr ...

Opens in a new tab or window In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without ...

Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...

At 10.30am on a chilly Saturday the queue outside Manze’s pie-and-mash shop on Deptford High Street stretches 50 metres down the street. The restaurant has been a fixture of the south-east ...

Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales ...

Dale Sherman, author of the MASH FAQ, offers of the series' success, "I really think it has to do with the writing and acting more than anything else. I don't think anybody was really wanting to ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...